Cindy Q. Zhou
YOU?
Author Swipe
View article: Dextran sodium sulfate confounds causal role of periodontitis in inflammatory bowel disease
Dextran sodium sulfate confounds causal role of periodontitis in inflammatory bowel disease Open
Background Emerging evidence supports a bidirectional link between periodontitis and inflammatory bowel disease (IBD). To investigate this relationship, experimental models commonly use dextran sodium sulfate (DSS) to induce colitis. Howev…
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Constitutively active mutant EGFR is one of the major oncogenic drivers in non–small cell lung cancer (NSCLC). Targeted therapy using EGFR tyrosine kinase inhibitor (TKI) is a first-line option in patients that have metastatic or recurring…
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Selected characteristics of the PDX models used in the study. Data were extracted from the database of The Jackson Laboratory
View article: Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Constitutively active mutant EGFR is one of the major oncogenic drivers in non–small cell lung cancer (NSCLC). Targeted therapy using EGFR tyrosine kinase inhibitor (TKI) is a first-line option in patients that have metastatic or recurring…
View article: Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Constitutively active mutant EGFR is one of the major oncogenic drivers in non–small cell lung cancer (NSCLC). Targeted therapy using EGFR tyrosine kinase inhibitor (TKI) is a first-line option in patients that have metastatic or recurring…
View article: Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Anti-HDGF antibody enhances the efficacy of EGFR-targeted therapy. Mice with established PDXs of NSCLC tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody. A and B, Spider plot of…
View article: Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
HDGF expression in naïve and osimertinib-treated PDX tumors. Formalin-fixed, paraffin-embedded sections of TM00219 PDX tumors were stained with mouse anti–HDGF antibody T221. Representative fields (10×) of staining in naïve, osimertinib-tr…
View article: Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
HDGF expression in naïve and osimertinib-treated PDX tumors. Formalin-fixed, paraffin-embedded sections of TM00219 PDX tumors were stained with mouse anti–HDGF antibody T221. Representative fields (10×) of staining in naïve, osimertinib-tr…
View article: Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Dynamics of EGFR signaling during the early stage of osimertinib treatment. Mice bearing TM00219 tumors were treated with osimertinib (10 mg/kg per os, every 24 hours) for up to 72 hours. Duplicate tumor samples were serially collected at …
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Dynamics of EGFR signaling during the early stage of osimertinib treatment. Mice bearing TM00219 tumors were treated with osimertinib (10 mg/kg per os, every 24 hours) for up to 72 hours. Duplicate tumor samples were serially collected at …
View article: Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Effect of anti-HDGF antibody on EGFR signaling in osimertinib-treated TM00219 PDX tumor. Mice with established TM00219 PDX tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody H3. …
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Characteristics of HDGF binding by humanized anti-HDGF antibody H3. A, Binding of native HDGF by anti-HDGF antibody H3. Recombinant H3 was immobilized on protein G agarose beads and used to capture HDGF in HEK293 lysate. Lane 1, H3 loaded-…
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Selected characteristics of the PDX models used in the study. Data were extracted from the database of The Jackson Laboratory
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Anti-HDGF antibody enhances the efficacy of EGFR-targeted therapy. Mice with established PDXs of NSCLC tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody. A and B, Spider plot of…